Alex Biese

The TILVANCE-301trial, expected to be completed in 2030, is the latest study of what has been described as one of the “phenomenal discoveries in melanoma.”

The NALIRIFOX regimen of Onivyde plus 5-fluorouracil/leucovorin and oxaliplatin has been shown to have survival and disease progression benefits for patients with pancreatic cancer in a clinical trial setting.

Factors including race, insurance and treatment history have been associated with increased cardiovascular disease, risk factors and mortality among cancer survivors, including those with a history of pediatric cancer, according to recent research.

Patients with platinum-resistant or refractory ovarian cancer experienced deep responses and survival benefits in a trial assessing immunotherapy with chemotherapy.

A significant majority of patients with early-stage classical Hodgkin lymphoma demonstrated a complete response to treatment with Adcetris, Opdivo and chemotherapy.

Mindfulness meditation can make a big difference in the treatment experience of patients.

For patients who don’t speak English, there can be additional obstacles during their cancer journey. Resources, family, care providers, fellow patients and the law are on their side.

Watch Dr. Laura C. Michaelis, from the Medical College of Wisconsin, discuss the current and future management of essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Watch Dr. Lucia Masarova, from MD Anderson Cancer Center, discuss risk stratifying patients with essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Participants in the RESTORE study, results of which were presented this weekend at ASCO, saw “significant improvements” in depression and anxiety symptoms after using the Attune app.

‘Forwards,’ the new album by Mike Peters and the Alarm, was written while he was hospitalized for treatment of chronic lymphocyte leukemia and pneumonia.

Two years after receiving FDA approval, Besremi is a preferred treatment option in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.

“Nobody’s going to fight for your life the way you’re going to fight for your life,” Hodgkin’s lymphoma survivor, Paula Ngon, told CURE®.

Many cancer centers and nonprofit organizations offer resources for patients with cancer and their caregivers to see the support they need to navigate diagnosis, treatment and survivorship.

Campaigns such as #BrewStacheStrong and Melesa’s Wings are uniting brewers and craft beer aficionados as they raise funds and awareness for cancer.

Work is underway in the global phase 3 HARMONi study evaluating the combination of ivonescimab and chemotherapy in the treatment of patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer.

Watch Dr. Jyoti Malhotra, from City of Hope Orange County, discuss targeted therapy, during the CURE® Educated Patient® Lung Cancer Summit.

Dr. Dawn Mussallem of the Mayo Clinic tells CURE®’s “Cancer Horizons” podcast about how surviving stage 4 non-Hodgkin’s lymphoma and being a heart transplant recipient helps her connect with her patients.

Watch an expert discuss biomarker testing during the CURE® Educated Patient® Lung Cancer Summit.

Breyanzi has reportedly shown promising effects for patients with relapsed or refractory follicular lymphoma and B-cell non-Hodgkin lymphoma.

Depression reduces the likelihood of receiving recommend treatment, which can affect survival, according to a Kentucky-based study of patients with breast cancer.

A clinical trial is underway for STX-478, a potential new treatment for breast cancer and other tumors, with initial results expected later this year.

TPST-1120 is displaying potential in combatting hepatocellular carcinoma, the fastest-rising cause of cancer-related death in the United States.

A team from Rutgers University has figured out the science behind once-dormant, self-reviving cells, and the discovery may help predict which patients will experience relapse.

Researchers have found that nothing beats direct attention from a care provider to inspire exercise among young women who have been recently diagnosed with breast cancer.

Tislelizumab was found to improve overall survival among patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

The makers of a new treatment for metastatic, castration-resistant prostate cancer are working to bring it to patients “as quickly as possible.”

Watch Dr. Brandon Blue, from Moffitt Cancer Center, discuss health disparities during the CURE Educated Patient Multiple Myeloma Summit.

More than 80% of cancer survivors who use cannabis do so for medical reasons, but there remains “a lack of strong evidence” for the drug’s effectiveness, according to the authors of a new study.

The FDA has accepted a supplemental Biologics License Application for moving up the use of Abecma, a CAR-T cell therapy, for adult patients with multiple myeloma.